I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EULAR 2025

-
Coming soon
02:30 PM
Duration 90mins Barcelona
Obinutuzumab demonstrates consistent benefit across numerous primary endpoint definitions using REGENCY study results of patients with active lupus nephritis
Rovin BH, Pendergraft III WF, Lightstone L, Amoura Z, Furie RA, Hassan I, Yoo B, Martins E, Hans A-C, Omachi TA, Schindler T, Garg JP, Henes J, Malvar A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 AM
Duration 60mins Barcelona, Spain
Severe COVID-19 amongst patients with systemic lupus erythematosus and lupus nephritis between 2020 and 2024: a retrospective cohort study using US-based electronic health records
Lindsay L, Trinh H, Wang S, Pendergraft III WF, Kirchner P, Yazdany J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 75mins Barcelona, Spain
Full Symposium: Advances in lupus nephritis: what’s next?
Edward Vital, Johanna Mucke, Richard Furie, Ana Malvar
Notify me

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
07:30 AM
Duration 60mins Barcelona, Spain
Kidney-related outcomes with obinutuzumab in patients with active lupus nephritis: a pre-specified exploratory analysis of the REGENCY study
Rovin BH, Garg JP, Lightstone L, Daugas E, Furie RA, Omachi T, Hassan I, Martins E, Schindler T, Pendergraft III WF, Quintana L, Leszczynski P, Malvar A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Barcelona, Spain
Obinutuzumab shows promise in lupus nephritis regardless of baseline serological biomarkers: an exploratory post hoc analysis of the phase II NOBILITY study
Vital EM, Vargas B, Rae J, Wang T, Hackney J, Looney CM, Pendergraft III WF, Lightstone L, Rovin BH, Furie RA, Raghu H

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:15 AM
Duration 90mins Barcelona, Spain
A Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab▼ in participants with systemic lupus erythematosus
Chindalore VL, Martins E, Pendergraft III WF, Sheng R, Schroeder A, Gearhart L, Mody H, Mao A, Garg JP, Dankiewicz-Fares I, Agachi S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 90mins Barcelona, Spain
Interim population pharmacokinetic analysis of obinutuzumab in adolescents with active class III or IV lupus nephritis and simulations to determine obinutuzumab dose selection in a younger paediatric cohort aged 5 to <12 years in the POSTERITY clinical study
Cossin V, Meneses-Lorente G; D'Arienzo V, Lanza B, Van Someren C, Wood N, Lehane PB

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar